Oncology Frontier: Is there any role for transplantation in the management of CTCL?

　　《肿瘤瞭望》：干细胞移植治疗CTCL有效吗？

　　Dr Prince: I think autologous transplantation has a minimal role， if any. There may be a role in patients with aggressive transformed disease in the hope that we may be able to get rid of the aggressive element and be able to manage the lower-grade element in the longer term (recognizing that we are probably not going to cure anyone). But we know that the disease is highly immune modulated， so allogeneic transplantation looks very exciting. The average age of patients is seventy years， so it is not going to be suitable for the majority of patients， but certainly the outcomes would be improved with Sézary Syndrome with allogeneic transplantation or tumor stage disease that is picked up relatively early (noting that allogeneic transplantation should not be considered as a final treatment but should be used in any younger patients with this otherwise incurable disease).

　　Prince博士：我认为自体移植治疗CTCL效果极小。对于侵袭性强的转化型淋巴瘤作用多一些，有望通过自体移植改变肿瘤的侵袭性，对疾病进行长期的控制和管理（治愈几乎不可能）。CTCL 细胞具有免疫调节能力，因此同种异体移植治疗CTCL令人期待。异体移植适用于年纪较轻的患者，CTCL患者的平均年龄为70岁，所以大部分患者不适合这种疗法。异体移植可改善塞扎里综合征患者以及早期患者的治疗效果，但不是最好的治疗方法。